Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exoASO-STAT3
- Development stage
- Discontinued
- Lead developer
- Codiak BioSciences
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal
01
Overview
exoASO-STAT3 is an investigational **exosome-based therapeutic** developed by Codiak BioSciences in collaboration with Jazz Pharmaceuticals. The candidate consists of engineered exosomes loaded with an **antisense oligonucleotide** designed to inhibit **signal transducer and activator of transcription 3** signaling, a transcription factor implicated in oncogenic signaling across hematologic malignancies and solid tumors. The program was part of a broader exosome therapeutics collaboration focused on oncology targets, but development of exoASO-STAT3 was discontinued in 2021 before clinical advancement was established.
- Other names
- STAT3-targeting exosome-delivered antisense oligonucleotideSTAT-3-targeting exosome-delivered antisense oligonucleotideSTAT 3-targeting exosome-delivered antisense oligonucleotide
02
Targets
STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on exoASO-STAT3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exoASO-STAT3.